Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections

Acta Tropica

Volumn 90, Issue 2, 2004, Pages 191-203

  Chatterjee, Shyama ^a   Mbaye, Amadou ^b   Alfidja, Agaicha T ^c   Weyler, Joost ^a   Scott, Janet T ^d   Van Damme, Pierre ^a   Van De Vijver, Koen ^a   Deelder, André ^e   Van Marck, Eric A E ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ESPOIR ^*  (Senegal)

^c Centre Hospitalier Universitaire Dakar   (Senegal)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Morbidity; Neuropeptide; Periportal fibrosis; Schistosomiasis; Somatostatin

Indexed keywords

SOMATOSTATIN;

SCHISTOSOMIASIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ASCITES; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HEIGHT; HEPATOMEGALY; HUMAN; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OCCUPATION; PARASITE; PROBABILITY; QUESTIONNAIRE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SEX RATIO; SPLENOMEGALY; WEIGHT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; SCHISTOSOMIASIS MANSONI; SOMATOSTATIN;

RODENTIA; SCHISTOSOMA; SCHISTOSOMA MANSONI;

EID: 1442359457     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2003.12.002     Document Type: Article

References (34)

1. Avgerinos A., Nevens F., Raptis S., Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomized trial. Lancet. 350:1997;1495-1499.
2. Bissette G., Myers B. Somatostatin in Alzheimer's disease and depression. Life Sci. 51:1992;1389-1410.
3. Bloom S.R., Polak J. Somatostatin. Br. Med. J. 295:1987;288-290.
4. Blum A.M., Metwali A., Mathew R.C., Cook G., Elliott D., Weinstock J.V. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J. Immunol. 149:1992;3621-3626.
5. Bradley D.J. Regulation of parasite populations. A general theory of the epidemiology and control of parasite infections. Trans. R. Soc. Trop. Med. Hyg. 66:1972;697-708.
6. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179:1973;77-79.
7. Butterworth A.E., Bensted-Smith R., Capron A., Capron M., Dalton P.R., Dunne D.W., Grzych J.M., Kariuki H.C., Khalife J., Koech D.K., Mugambi M., Ouma J.H., Arap Siongok T.K., Sturrock R.F. Immunity in human schistosomiasis mansoni: prevention by blocking antibodies of the expression of immunity in young children. Parasitology. 94:1987;281-300.
8. Butterworth A.E., Hagan P. Immunity in human schistosomiasis. Parasitol. Today. 3:1987;11-16.
9. Chatterjee S., Mbaye A., Van Marck E. Lower levels of the circulating neuropeptide somatostatin in Schistosoma mansoni infected patients may have pathological significance. Trop. Med. Int. Health. 8:2003;33-36.
10. Chatterjee S., Van Marck E. The role of somatostatin in schistosomiasis: a basis for immunomodulation in host-parasite interactions? Trop. Med. Int. Health. 6:2001;578-581.
11. Chatterjee S., De Man J., Van Marck E. Somatostatin and intestinal schistosomiasis: therapeutic and neuropathological implications in host-parasite interactions. Trop. Med. Int. Health. 6:2001a;1008-1015.
12. Chatterjee S., Mbaye A., Weyler J., Van Marck E. Severe morbidity caused by Schistosoma mansoni in northern Senegal: does the neuropeptide hormone somatostatin determine morbidity? Acta Gastro-Enterol. Belg. 64:2001b;A05.
13. Chatterjee S., Mbaye A., De Man J., Van Marck E. Does the neuropeptide somatostatin have a therapeutic role in schistosomiasis? Trends Parasitol. 18:2002;295-298.
14. Chen, M.G., Mott, K.E., 1988. Progress in assessment of morbidity to Schistosoma mansoni infection. A review of recent literature. Trop. Dis. Bull. 85, RI-R56.
15. Elliott D.E., Li J., Blum A., Metwali A., Patel Y.C., Weinstock J.V. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur. J. Immunol. 29:1999;2454-2463.
16. Elliott D.E., Weinstock J.V. Granulomas in murine Schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Metabolism. 45:1996;88-90.
17. Elliott D.E., Metwali A., Blum A., Sandor M., Lynch R., Weinstock J.V. T lymphocytes isolated from the hepatic granulomas of schistosome-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA. J. Immunol. 153:1994;1180-1186.
18. Hagan P. Reinfection, exposure and immunity in human schistosomiasis. Parasitol. Today. 8:1992;12-16.
19. Jacobs, W., 1998. Schistosoma mansoni-induced hepatic and intestinal damage: a morphological study of granulomogenesis, fibro genesis and immune modulation. Ph.D. thesis, University of Antwerp, Belgium.
20. Mansy S.S., Yehia H.A., Hassan M.M., Hassan E.A., Youssef M.M., Hadi A.A., Mackenzie C.D. Effect of octreotide on the pathology of hepatic schistosomiasis. Arzneimittelforschung. 48:1998;855-861.
21. Reynaert H., Vaeyens F., Qin H., Hellemans K., Chatterjee N., Winand D., Urbain D., Geerts A. Activated rat hepatic stellate cells express somatostatin receptor subtypes 1, 2 and 3. Hepatology. 30:1999;236A.
22. Reynaert H., Vaeyens F., Rombouts K., Chatterjee N., Urbain D., Geerts A. Effect of somatostatin-14 on extracellular matrix expression by activated rat hepatic stellate cells. J. Hepatol. 34:2001;6.
23. Scarpignato C. Somatostatin in digestive diseases: improving the treatment options. Digestion. 60:1999;S1-S72.
24. Schusdziarra, V., 1996. Somatostatin: biological actions and pathophysiology. In: Scarpignato, C. (Ed.), Octreotide: From Basic Science to Clinical Medicine. Karger, Basel, pp. 35-53.
25. Stelma, F.F., 1997. Immuno-epidemiology, morbidity and chemotherapy in a community recently exposed to Schistosoma mansoni infection. A study in northern Senegal. Ph.D. thesis, University of Leiden, The Netherlands.
26. Stelma F.F., Talla I., Polman K., Niang M., Sturrock R.F., Deelder A.M., Gryseels B. Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal. Am. J. Trop. Med. Hyg. 49:1993;701-706.
27. Warren K.S. Regulation of the prevalence and intensity of schistosomiasis in man: immunology or ecology? J. Infect. Dis. 127:1973;595-609.
28. Weinstock J.V., Elliott D. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur. J. Endocrinol. 143:2000;S15-S19.
29. Weinstock J.V., Elliott D. The substance P and somatostatin interferon-gamma immunoregulatory circuit. Ann. N. Y. Acad. Sci. 840:1998;532-539.
30. Weinstock J.V. Macrophages within the granulomas of murine Schistosoma mansoni are a source of a somatostatin 1-14-like molecule. Cell Immunol. 131:1990;381-390.
31. WHO Expert Committee, 1993. The control of schistosomiasis. World Health Organisation Technical Report Series 830, pp. 1-86.
32. WHO Workshop Report, 2000. Ultrasound in schistosomiasis: a practical guide to the standardized use of ultrasonography for assessment of schistosomiasis-related morbidity. TDR/STR/SCH/00.1, pp. 1-49.
33. Wyler D.J. Why does liver fibrosis occur in schistosomiasis? Parasitol. Today. 8:1992a;277-279.
34. Wyler D.J. Molecular and cellular basis of hepatic fibrogenesis in experimental Schistosomiasis mansoni infection. Membr. Inst. Osw. Cruz. 87:1992b;117-125.